| abstract |
The present invention relates to compounds of the formula (I) (see formula) wherein R 1 is hydrogen, lower alkyl, lower alkoxy, halogen or lower alkyl substituted by halogen; R is hydrogen or halogen; or R1 and R are together with the carbon atom to which they bind -CH = CH-CH = CH-; R2 is hydrogen, lower alkyl, phenyl optionally substituted by halogen, or is hetaryl, optionally substituted by lower alkyl; R3 is hydrogen, lower alkyl, phenyl, benzyl, lower alkenyl, lower alkoxy, phenyloxy, benzyloxy, S-lower alkyl, halogen, CN, lower alkyl substituted by halogen or O-lower alkyl substituted by halogen; R4 is hydrogen or lower alkyl, aryl is phenyl or naphthyl; n is 1, 2 or 3; m is 1 or 2; and pharmaceutically acceptable acid addition salts and tautomeric forms thereof. It is found that the compounds of formula I have good activity in the 5-HT5A receptor. Therefore, the invention provides the use of a compound of the formula I or a pharmaceutically acceptable salt thereof for the manufacture of medicaments for the treatment of certain CNS disorders. |